Vaxneuvance 2 mcg (Pneumococcal Polysaccharide Serotype 14) Suspension

VAXNEUVANCE 2 MCG is a pneumococcal polysaccharide vaccine designed to protect against infections caused by Streptococcus pneumoniae. This intramuscular suspension is manufactured by Merck Canada Inc. and is commonly used for preventive care.

VAXNEUVANCE 2 MCG is primarily used to prevent infections caused by the pneumococcal bacterium. It targets serotype 14, which is one of the strains responsible for conditions like pneumonia, meningitis, and bacteremia. This vaccine is often recommended for individuals at higher risk of pneumococcal infections, including those with weakened immune systems or chronic health conditions.

Common effects of VAXNEUVANCE 2 MCG may include mild soreness, redness, or swelling at the injection site. Some individuals might experience temporary fever, fatigue, or muscle aches following vaccination. These effects are generally mild and short-lived.

Before receiving VAXNEUVANCE 2 MCG, inform your healthcare provider about any allergies, especially to yeast or any components of the vaccine. Individuals with a history of severe allergic reactions to previous pneumococcal vaccines should exercise caution. Always follow the advice of a healthcare professional regarding vaccination.

VAXNEUVANCE 2 MCG may interact with certain medications that affect the immune system. It is important to discuss all current medications with a healthcare provider before receiving this vaccine. Additionally, individuals with compromised immune systems may have a different response to the vaccine.